ABVC · Abvc Biopharma, Inc.
Market Cap
$23.46M
Shares
26.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.86
Open$0.84
Day$0.83–0.90
52W close$0.71–3.29
Avg vol 30d98K
Short int429K · 1.6% float · 3.5d
Short vol46%
DataJul 2023–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Jul 25, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
−28%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−41%
trailing
YTD return
−60%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+7% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.61% of float · ▼ -2.8% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
15 holders — near 3-yr high, broad support
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
+234%
Y/Y
Gross margin
100%
expanding
EPS growth
+7%
Y/Y
Free cash flow
$-3.0M
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+7% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.61% of float · ▼ -2.8% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
15 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 6%
Range high $3
vs 200-day avg -45%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABVC
this stock
Abvc Biopharma, Inc.
|
$23.46M | -59.7% | +234.3% | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Jul 25, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABVC | +2.1% | -17.6% | -41.3% | -15.1% | -59.7% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +1.6% | -18.8% | -54.5% | -17.8% | -72.2% |